Key 2026 clinical milestones: The recurrent cSCC pivotal trial is nearing completion with last patient treatments expected imminently and topline data planned for H2 2026, while a GBM pilot safety ...
On Tuesday, March 10, 2026, PolyPid (NASDAQ:PYPD) presented at The Citizens Life Sciences Conference 2026, highlighting its strategic initiatives and future plans. The conference call underscored the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results